When mice with either VHL or PHD2 mutations develop pulmonary hypertension, it is HIF-2α (via concomitant deletion) that has been shown to be the critical downstream effector (Dai et al., 2018; Hickey et al., 2010; Kapitsinou et al., 2016). This evidence concerns the gene EGLN1 and pulmonary arterial hypertension.